 
 
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: Dojolvi® | UX-007 | UX007
                                 triheptanoin is an approved drug (FDA (2020)) Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: Triheptanoin is a medium-chain triglyceride that is administered as a rescue therapeutic in patients with long-chain fatty acid oxidation disorders [1].
                                    
                                 | 
 | |||||||||||||||||||||||||||||||||||
| References | 
| 1. Shirley M. (2020) Triheptanoin: First Approval. Drugs, 80 (15): 1595-1600. [PMID:32897506] | 
| 2. Vockley J, Burton B, Berry G, Longo N, Phillips J, Sanchez-Valle A, Chapman K, Tanpaiboon P, Grunewald S, Murphy E et al.. (2021) Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study. J Inherit Metab Dis, 44 (1): 253-263. [PMID:32885845] | 
| 3. Vockley J, Burton B, Berry GT, Longo N, Phillips J, Sanchez-Valle A, Tanpaiboon P, Grunewald S, Murphy E, Bowden A et al.. (2019) Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD). J Inherit Metab Dis, 42 (1): 169-177. [PMID:30740733] |